For US Healthcare Professionals only | Patients & Caregivers | Full Prescribing Information | Important Safety Information

Request a Thea Visit

Representatives are available in your area to discuss ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01% and answer any questions you may have. Fill out the form below, and someone will connect you with your area ZOLYMBUS™ representative.

All fields marked with an asterisk (*) are required.

X/Twitter

This field is for validation purposes and should be left unchanged.

Name*

First Name Last Name

Email Address*

Phone*

I am a(n):*

NPI #*

Practice Name*

State*

ZIP*

Spam Protection

INDICATIONS AND USAGE

ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01%, is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to bimatoprost or any other ingredients in this product.

WARNINGS AND PRECAUTIONS

Bimatoprost may cause changes to pigmented tissues. Most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. Iris pigmentation is likely to be permanent. Eyelid skin darkening and eyelash changes may be reversible.

Bimatoprost may cause gradual change to eyelashes including increased length, thickness, and number of lashes. These changes are usually reversible upon discontinuation of treatment.

Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular inflammation. ZOLYMBUS should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because inflammation may be exacerbated.

Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic products. ZOLYMBUS should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Contact lenses should be removed prior to the administration of ZOLYMBUS and may be reinserted 15 minutes after administration.

ADVERSE REACTIONS

Most common adverse reactions (≥10%) are conjunctival hyperemia (14%) and eye irritation (11%).

Please click here for the full Prescribing Information.

Request a Thea Visit

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

You are now leaving ZOLYMBUS.com

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS